As Congress continues to debate solutions to lower healthcare costs, biosimilars are a promising option. But uptake of biosimilars has been slow in the U.S., and few patients are seeing direct savings at the pharmacy counter.
Brian Lehman, Director of Patient Advocacy at Sandoz, explains how biosimilars play a role in patient care and result in cost savings to the healthcare system. Mary Jo Carden, Head of Policy, lays out policy actions to boost biosimilar use. And while biosimilars might not be a good fit for all patients, Terry and Dr. Bob look at the ways these medications can improve patient access for many individuals.
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Kate Pecora, Field Correspondent, Patients Rising
Dorothea Lantz, Patient Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: firstname.lastname@example.org
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.